Gyre Therapeutics (GYRE) Stock Price, News & Analysis

Company Overview

Gyre Therapeutics, Inc., a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases. In addition, it advances a product pipeline in China, including Pirfenidone, for dermatomyositis interstitial lung disease, systemic sclerosis-associated interstitial lung disease, and pneumoconiosis, as well as for diabetic kidney disease; and product candidates for acute-on-chronic liver failure, chronic obstructive pulmonary disease, and pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California.

Key Stats

• Today's Range: $6.57 to $7.04
• 50-Day Range: $6.65 to $10.18
• 52-Week Range: $6.11 to $19.00
• Volume: 103,460 shs
• Average Volume: 78,879 shs
• Market Capitalization: $623.50 million
• P/E Ratio: 332.67
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Buy

GYRE Stock Analysis - Frequently Asked Questions

How have GYRE shares performed this year?

Gyre Therapeutics' stock was trading at $12.10 at the beginning of the year. Since then, GYRE shares have decreased by 45.0% and is now trading at $6.65.

How were Gyre Therapeutics' earnings last quarter?

Gyre Therapeutics, Inc. (NASDAQ:GYRE) issued its quarterly earnings results on Friday, May, 9th. The company reported $0.03 EPS for the quarter, meeting the consensus estimate of $0.03. The business had revenue of $22.06 million for the quarter, compared to the consensus estimate of $28.40 million. Gyre Therapeutics had a trailing twelve-month return on equity of 9.73% and a net margin of 7.20%.

How do I buy shares of Gyre Therapeutics?

Shares of GYRE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Gyre Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Gyre Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Netflix (NFLX), Broadcom (AVGO), Palo Alto Networks (PANW) and Invesco QQQ (QQQ).

Company Calendar

• Last Earnings: 5/09/2025
• Today: 8/02/2025
• Next Earnings (Estimated): 8/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:GYRE
• Previous Symbol: NASDAQ:GYRE
• CIK: 1124105
• Web: www.catalystbiosciences.com
• Phone: (619) 949-3681
• Fax: 336-480-2107
• Employees: 40
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): $0.02
• Trailing P/E Ratio: 332.67
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $12.09 million
• Net Margins: 7.20%
• Pretax Margin: 15.27%
• Return on Equity: 9.73%
• Return on Assets: 7.66%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.60
• Quick Ratio: 3.19

Sales & Book Value

• Annual Sales: $105.76 million
• Price / Sales: 5.90
• Cash Flow: $0.19 per share
• Price / Cash Flow: 35.70
• Book Value: $1.05 per share
• Price / Book: 6.33

Miscellaneous

• Outstanding Shares: 93,760,000
• Free Float: 84,382,000
• Market Cap: $623.50 million
• Optionable: No Data
• Beta: 1.80